219 related articles for article (PubMed ID: 35068786)
1. Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia-A Prospective, Interventional, Pilot Study.
Rajesh NA; Drishya L; Ambati MMR; Narayanan AL; Alex M; R KK; Abraham JJ; Vijayakumar TM
J Clin Exp Hepatol; 2022; 12(1):61-67. PubMed ID: 35068786
[TBL] [Abstract][Full Text] [Related]
2. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.
Kaul U; Parmar D; Manjunath K; Shah M; Parmar K; Patil KP; Jaiswal A
Cardiovasc Diabetol; 2019 Jun; 18(1):80. PubMed ID: 31208414
[TBL] [Abstract][Full Text] [Related]
3. An Observational Study of Reduction in Glycemic Parameters and Liver Stiffness by Saroglitazar 4 mg in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
Mitra A
Cureus; 2020 Jul; 12(7):e9065. PubMed ID: 32782883
[TBL] [Abstract][Full Text] [Related]
4. Saroglitazar for Nonalcoholic Fatty Liver Disease: A Single Centre Experience in 91 Patients.
Padole P; Arora A; Sharma P; Chand P; Verma N; Kumar A
J Clin Exp Hepatol; 2022; 12(2):435-439. PubMed ID: 35535066
[TBL] [Abstract][Full Text] [Related]
5. Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis.
Siddiqui MS; Parmar D; Sheikh F; Sarin SK; Cisneros L; Gawrieh S; Momin T; Duseja A; Sanyal AJ
Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2597-2605.e2. PubMed ID: 36731585
[TBL] [Abstract][Full Text] [Related]
6. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study.
Goyal O; Nohria S; Goyal P; Kaur J; Sharma S; Sood A; Chhina RS
Sci Rep; 2020 Dec; 10(1):21117. PubMed ID: 33273703
[TBL] [Abstract][Full Text] [Related]
7. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
Gawrieh S; Noureddin M; Loo N; Mohseni R; Awasty V; Cusi K; Kowdley KV; Lai M; Schiff E; Parmar D; Patel P; Chalasani N
Hepatology; 2021 Oct; 74(4):1809-1824. PubMed ID: 33811367
[TBL] [Abstract][Full Text] [Related]
8. Clinical Case Series of Decrease in Shear Wave Elastography Values in Ten Diabetic Dyslipidemia Patients Having NAFLD with Saroglitazar 4 mg: An Indian Experience.
Roy S
Case Rep Med; 2020; 2020():4287075. PubMed ID: 32280349
[TBL] [Abstract][Full Text] [Related]
9. A Prospective Randomised Comparative Four-arm Intervention Study of Efficacy and Safety of Saroglitazar and Vitamin E in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH)-SVIN TRIAL.
Mir BA; Sharma B; Sharma R; Bodh V; Chauhan A; Majeed T; Haq I; Sharma N; Sharma D
J Clin Exp Hepatol; 2024; 14(5):101398. PubMed ID: 38628977
[TBL] [Abstract][Full Text] [Related]
10. Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients.
Shetty SR; Kumar S; Mathur RP; Sharma KH; Jaiswal AD
Indian Heart J; 2015; 67(1):23-6. PubMed ID: 25820046
[TBL] [Abstract][Full Text] [Related]
11. Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis.
Bandyopadhyay S; Samajdar SS; Das S
Clin Res Hepatol Gastroenterol; 2023 Aug; 47(7):102174. PubMed ID: 37380128
[TBL] [Abstract][Full Text] [Related]
12. Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).
Krishnappa M; Patil K; Parmar K; Trivedi P; Mody N; Shah C; Faldu K; Maroo S; ; Parmar D
Cardiovasc Diabetol; 2020 Jun; 19(1):93. PubMed ID: 32560724
[TBL] [Abstract][Full Text] [Related]
13. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of saroglitazar in real-world patients of non-alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center experience.
Chaudhuri S; Dutta A; Chakraborty SBD
JGH Open; 2023 Mar; 7(3):215-220. PubMed ID: 36968568
[TBL] [Abstract][Full Text] [Related]
15. Saroglitazar for the treatment of dyslipidemia in diabetic patients.
Joshi SR
Expert Opin Pharmacother; 2015 Mar; 16(4):597-606. PubMed ID: 25674933
[TBL] [Abstract][Full Text] [Related]
16. Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD).
Duseja A; Singh SP; De A; Madan K; Rao PN; Shukla A; Choudhuri G; Saigal S; Shalimar ; Arora A; Anand AC; Das A; Kumar A; Eapen CE; Devadas K; Shenoy KT; Panigrahi M; Wadhawan M; Rathi M; Kumar M; Choudhary NS; Saraf N; Nath P; Kar S; Alam S; Shah S; Nijhawan S; Acharya SK; Aggarwal V; Saraswat VA; Chawla YK
J Clin Exp Hepatol; 2023; 13(2):273-302. PubMed ID: 36950481
[TBL] [Abstract][Full Text] [Related]
17. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
18. Serum Ferritin level, microalbuminuria and non-alcoholic fatty liver disease in type 2 diabetic patients.
Amin RF; El Bendary AS; Ezzat SE; Mohamed WS
Diabetes Metab Syndr; 2019; 13(3):2226-2229. PubMed ID: 31235161
[TBL] [Abstract][Full Text] [Related]
19. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
Garvey WT; Mechanick JI; Brett EM; Garber AJ; Hurley DL; Jastreboff AM; Nadolsky K; Pessah-Pollack R; Plodkowski R;
Endocr Pract; 2016 Jul; 22 Suppl 3():1-203. PubMed ID: 27219496
[TBL] [Abstract][Full Text] [Related]
20. A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V).
Pai V; Paneerselvam A; Mukhopadhyay S; Bhansali A; Kamath D; Shankar V; Gambhire D; Jani RH; Joshi S; Patel P
J Diabetes Sci Technol; 2014 Jan; 8(1):132-141. PubMed ID: 24876549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
